Ciprofloxacin was one of the first antibiotics in the f1u oroquinolone class to be wide ly used . It offers good gra m-nega tive coverage, it is effective aga inst orga nisms such as Pseudomonas aeruginosa , and it is safe to the inner ear. However, it is not very effec tive as a syste mic treatm ent for many respir atory illne sses (e.g., comm unity -acq uired pneu mon ia) because of its poor gram -positive cove rage and hig her resistance rates . Other quinolone s may offer advantages over ciprofloxacin.
Respiratory quinolones
Th e limitations of cipro floxac in in the lower airway led to the development of the so-called respi ratory quinolones-I ev ofloxacin , ga tifloxac in, moxiftoxac in, and gemifloxaci n. These agents offer better gra m-pos itive coverage with lower resis tance rates. (Two other qu inolones, norfloxacin and lomefloxacin, are used primarily to treat urinary tract and prostate infections, and ofloxacin is anot her that is man ufact ured in a topical for m for ear and eye disease.)
Because cipro floxacin is not used to treat lower airway diseases, there are esse ntially no studies co mparing it wit h other quin olones in disease proc esses outside the ear. In Can ada, co mparisons among the respiratory quin olones them selves have indicated that levofloxacin is associated with an increasi ng rate of res istance to Streptoco ccus pn eumoniae in patients with com munity-acquired pne umonia.I As a res ult, levofloxacin has become less widely used for this indication. Otherwise, there is little difference among the resp irato ry quin olones.
Ototopicals
Th e qu inolone s have particul ar value as ototopical age nts because of their broad spec trum of antibac terial activity again st the otic pathogens. In add itio n, they provi de a high concentration of drug at the site of infection, so even otic diseases ca used by bacteria that do show some resistance can be rou tinely eradicated. A third important aspect of the quinolones is t hat they do not appear to be ototox ic.
As is the case with lower airway diseases, there are no head-to-h ead comparisons of quinolones alone in otic disease. Th ere are, however, co mparisons of quin olones with a stero id co mponent to other qu ino!ones without a stero id compo nent. In one of these studies, researchers comp ared ciprofloxacin/dexamethasone otic with ofloxacin 0.3 % otic and found that the combination agent was more effective in treatin g ac ute otiti s medi a throu gh tympanostom y tube s (AOMT) .2In that randomized, multi center,controlled clinical trial, the per-protoco l ana lysis revealed that ciprofloxacin/dexamet haso ne otic administered 2 times per day for 7 days achieved clinical cures in 86% of AOMT patients, compared with a 79% cli nical cure rate for ofloxaci n solution admi nistere d 2 times per day for 10 days. Amo ng culture-pos itive patients, clin ical cure rates were 90 and 79%, res pec tively, and the correspo ndi ng microbiologic eradic ation rates were 9 1 and 82% (figure).
Ph arm acokin et ics may help ex pla in ciprofloxacin 's success in treatin g otic disease processes. The area under the inhibitory curve (AUIC) for ciprofloxacin aga inst P aeru ginosa is approximate ly 4 times grea ter than the AUIC for ofloxacin.' Studies have show n that exposure to antibiotic regi mens that have low AUIC values ca n prolong the time to bacterial eradication and allow resistant bacteria to emerge.'>
New ototopical in development
New otic quinolone formulations are being investigated as a possi ble treatment for AOMT, otitis externa, otitis media with a perforated tymp anic membrane, and chro nic suppurat ive otitis med ia. For example, preliminary testing is under way to determine if a fixed combination of moxifloxacin and dexamethaso ne mig ht be more potent than ciproftoxacin/dexamethasone. It has already been show n ( I) that moxifloxacin alone is more potent than both ciprofloxacin and ofloxac in against gram-pos itive path ogen s, (2) that moxifloxacin 's activity against lessquin olone-susceptible gra m-nega tive iso lates other than P aerug inosa may be comp arabl e to that of ciprofloxacin and ofloxac in, and (3) that moxi floxac in is less affec ted than ciprofloxaci n by mechanisms respo nsible for increasing quinolone resistance in stap hy lococci." Moxifloxac in's ability to penetrate conjunctiva l tissue was rece ntly com pared with that of seve ral other quinolones. Wagner et al showed that the concentration of moxifloxacin in conj unctiva was grea ter than that of ciproftoxac in, gatiftoxacin, ofloxacin, and levoflo xacin. ?
It has been suggested that moxifloxacin' s better tissue penetration may be attributable to the fact that it exhibit s what is termed biphasic solubility-that is, it is both lipophilic and hydrophilic , whereas the other f1u oroquinolones are not." Ultim ately, the theoretic al benefits of the newer generation of topical quinolones must be substantiated in head-to-head clinical trials. 
